Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis

2009 ◽  
Vol 96 (6) ◽  
pp. E30-E44 ◽  
Author(s):  
N. Ismaili ◽  
S. Arifi ◽  
A. Flechon ◽  
O. El Mesbahi ◽  
J.-Y. Blay ◽  
...  
Keyword(s):  
Cell Cancer ◽  
Small Cell ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder ◽  
Bladder Pathology

Small cell cancer of the bladder: The Léon-Bérard Cancer Center experience

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16147-16147
Author(s):  
I. N. Nabil ◽  
F. Elkarak ◽  
A. Flechon ◽  
J. Droz
Keyword(s):  
Cell Cancer ◽  
Small Cell ◽  
Cancer Center ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder

scholarly journals Small cell cancer of the bladder: The Leon-Berard cancer centre experience

2008 ◽  
Vol 24 (4) ◽  
pp. 494 ◽  
Author(s):  
Nabil Ismaili ◽  
Fadi Elkarak ◽  
PierreEtienne Heudel ◽  
Aude Flechon ◽  
JeanPierre Droz
Keyword(s):  
Cell Cancer ◽  
Small Cell ◽  
Cancer Centre ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder

scholarly journals Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center

Cureus ◽  
2015 ◽  
Author(s):  
Shahida Ahmed ◽  
Sam Neufeld ◽  
Tadeusz J Kroczak ◽  
Bashir Bashir ◽  
Naseer Ahmed ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Cell Cancer ◽  
Small Cell ◽  
Cancer Center ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder ◽  
Tertiary Cancer Center

Analysis of treatment for small cell cancer of the bladder and report of three cases

Urology ◽  
2004 ◽  
Vol 64 (3) ◽  
pp. 494-498 ◽  
Author(s):  
Edward Karpman ◽  
Zelanna Goldberg ◽  
Amir Saffarian ◽  
Regina Gandour-Edwards ◽  
Lars M. Ellison ◽  
...  
Keyword(s):  
Cell Cancer ◽  
Small Cell ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder

Case 2: Recurrent thromboembolism despite adequate oral anticoagulation – Trousseau’s syndrome

1999 ◽  
Vol 56 (9) ◽  
pp. 481-483
Author(s):  
Züger ◽  
Demarmels Biasiutti
Keyword(s):  
Oral Anticoagulation ◽  
Cell Cancer ◽  
Small Cell ◽  
Niedermolekulares Heparin ◽  
Small Cell Cancer ◽  
Trousseau’S Syndrome ◽  
Cancer Of The Lung

Wir berichten über einen 76jährigen Patienten, welcher trotz gut eingestellter oraler Antikoagulation mit Phenprocoumon rezidivierende Thrombosen erlitt bei leichtgradiger chronischer disseminierter intravasaler Gerinnung. Die Abklärungen ergaben das Vorliegen eines Bronchus-Karzinoms (Non small cell cancer of the lung, NSCCL) mit hilären und mediastinalen Lymphknotenmetastasen. Aufgrund der Assoziation von rezidivierenden Thrombosen, aktivierter Gerinnung und Tumorleiden wurde die Diagnose eines Trousseau Syndroms gestellt. Basierend auf Fallberichten aus der Literatur wurde die Therapie auf intravenöses Heparin gewechselt, welches die thrombotische Koagulopathie stoppte. Aus praktischen Gründen erfolgte dann eine Umstellung der Therapie auf subcutanes niedermolekulares Heparin in therapeutischer Dosierung, welches während 6.5 Monaten ebenso effektiv war und eine Alternative zur etablierten Therapie mit unfraktioniertem Heparin bei Trousseau Syndrom darstellen dürfte.

Extrapulmonary Small Cell Cancer: A New Insight into a Rare Disease

Oncology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Leora Brazg Ferro ◽  
Ido Wolf ◽  
Shira Peleg Hasson ◽  
Inbal Golomb ◽  
Ester Osher ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Response Rate ◽  
Medical Center ◽  
Cell Cancer ◽  
Small Cell ◽  
Ki 67 ◽  
Small Cell Cancer ◽  
Pathological Characteristics ◽  
Results Of Treatment

<b><i>Introduction:</i></b> Extrapulmonary small-cell cancer (EPSCC) is a relatively rare malignancy. The management of EPSCC is usually extrapolated from small-cell lung cancer (SCLC). In spite of the morphological similarity of the 2 malignancies, there are many differences in clinical features, prognosis, and recommendations of treatment of these disorders. The data on the correlation of clinical-pathological characteristics of EPSCC and treatment results is scarce. <b><i>Materials and Methods:</i></b> This retrospective analysis of 41 consecutively treated patients diagnosed with EPSCC in 2015–2018 was performed in a tertiary medical center. The correlation between the clinical and pathological characteristics and the treatment outcome (response rate, disease-free interval, and overall medial survival) was done using the standard statistics, Kaplan-Meier method, and multivariate analyses. The stratification was done on the stage of the disease, Ki-67 proliferative index, the location of the tumor, and smoking. <b><i>Results:</i></b> Forty-one patients were included with a median age of 66.3 years. The most common primary site was the gastrointestinal tract (28, 68.3%) including the pancreas. The most common distant metastasis site was the liver (23, 56.1%). Only 2 patients (4.9%) had brain metastases. Unlike in SCLC, most patients did not have any history of smoking (23, 56.1%). Nineteen patients with metastatic disease received systemic treatment, mostly cisplatin-based chemotherapy, with a response rate of 57.9%. The results of treatment were significantly better in patients with disseminated EPSCC with Ki-67 &#x3c;55%, while its role in limited disease was nonsignificant. <b><i>Discussion:</i></b> The results of our study show the unique entity of EPSCC. The rarity of brain metastases proves that prophylactic brain irradiation should not be recommended in practice. The provocative idea of prophylactic liver irradiation in limited-stage EPSCC of gastrointestinal origin can be evaluated in future studies. The predictive role of Ki-67 is important in metastatic EPSCC. There is probably no role of smoking in developing EPSCC.

Sign in / Sign up

Export Citation Format

Share Document